HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Enforcement Priorities: Eye Products, Dual Drug/Cosmetic Firms

This article was originally published in The Rose Sheet

Executive Summary

When FDA inspects a facility producing both drugs and cosmetics, the manufacturer should be using one standard and that’s the drug standard, says Karyn Campbell, director of the investigations branch at FDA’s Philadelphia District Office.

You may also be interested in...

FDA Warns Foreign Personal-Care Firms For Monograph, GMP Violations

An August letter to Jabones Pardo is the latest in a string of FDA warnings to international firms that market personal-care products for acne treatment, pain relief and other indications in violation of U.S. drug regulations. Warnings to OTC product firms outside the U.S. over the past two years reflect the higher priority FDA has assigned to inspecting international firms.

Cosmetic User Fees, FDA Warnings, California: Top “Rose Sheet” Topics Of 2012

“The Rose Sheet” offers an overview of the year in cosmetics, analyzing 2012’s biggest news and the publication’s most-read stories. Highlights include a proposal in Obama’s 2013 budget request to institute cosmetics user fees, the rash of late-year warning letters and regulatory developments in California.

FDA Flags Chinese Personal-Care Firm For Drug GMP Failings

The agency will pursue cosmetics and personal-care product companies as pharmaceutical manufacturers if their product labeling strays into drug territory. FDA’s warning letter to Shanghai Huhui Daily Use Chemical Products says its skin protectant cream does not comply with the OTC monograph.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts